Working… Menu

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00085020
Recruitment Status : Completed
First Posted : June 11, 2004
Last Update Posted : August 3, 2020
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

Brief Summary:

RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Giving GW572016 with trastuzumab may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of GW572016 when given together with trastuzumab in treating patients with metastatic breast cancer that overexpresses HER2/neu.

Condition or disease Intervention/treatment Phase
Breast Cancer Biological: trastuzumab Drug: lapatinib ditosylate Phase 1

Detailed Description:



  • Determine the optimally tolerated regimen of GW572016 when administered with trastuzumab (Herceptin^®) in patients with metastatic breast cancer that overexpresses HER2/neu.
  • Determine the safety and tolerability of this regimen in these patients.


  • Determine the pharmacokinetic parameters of this regimen in these patients.
  • Determine the clinical response in patients treated with this regimen.

OUTLINE: This is an open-label, multicenter, dose-escalation study of GW572016.

Patients receive oral GW572016 once daily on days 1-28 and trastuzumab (Herceptin^®) IV over 90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of GW572016 until the optimally tolerated regimen (OTR) is determined. The OTR is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the OTR is determined, 10-18 additional patients are entered and treated at the OTR.

Patients are followed at 28 days.

PROJECTED ACCRUAL: A total of 3-35 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Trastuzumab [Herceptin†]
Study Start Date : March 2004
Actual Primary Completion Date : December 2004
Actual Study Completion Date : February 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed breast cancer
  • Metastatic disease
  • Measurable or evaluable disease
  • HER2/neu overexpression (2+ or 3+) confirmed by immunohistochemistry and/or HER2 gene amplification by fluorescence in situ hybridization
  • Brain metastases treated by surgery and/or radiotherapy allowed provided the following criteria are met:

    • Neurologic status stable 2 weeks after discontinuing dexamethasone
    • No concurrent anticonvulsants that induce metabolism (e.g., phenytoin, carbamazepine, or phenobarbital)
  • 18 and over
  • Male or female
  • Karnofsky 70-100%
  • Life expectancy, At least 12 weeks
  • Hematopoietic

    • Absolute granulocyte count ≥ 1,500/mm^3
    • Platelet count ≥ 100,000/mm^3
    • Hemoglobin ≥ 9 g/dL
    • AST and ALT ≤ 3 times upper limit of normal (ULN) (5 times ULN if patient has liver metastases)
    • Bilirubin < 1.5 mg/dL
    • Creatinine clearance > 30 mL/min
  • Cardiovascular

    • LVEF > 50%
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 4 weeks after study participation
  • Adequate venous access
  • Able to swallow and retain oral medication
  • Prior adjuvant/neoadjuvant chemotherapy allowed
  • More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin.
  • More than 4 weeks since prior radiotherapy
  • More than 4 weeks since prior major surgery
  • Recovered from all prior therapy
  • More than 28 days since prior participation in another investigational study
  • More than 28 days since prior investigational drugs

Exclusion Criteria:

  • extensive tumor, pleural effusions, or parenchymal masses) resulting in dyspnea at rest
  • uncontrolled brain metastases or leptomeningeal disease
  • prior myocardial infarction
  • pre-existing cardiac dysfunction (e.g., congestive heart failure)
  • clinically significant cardiac disease
  • angina pectoris
  • symptomatic intrinsic pulmonary disease (e.g., asthma or chronic obstructive pulmonary disease) resulting in dyspnea at rest
  • pregnant or nursing
  • active infection
  • known hypersensitivity to Chinese Hamster Ovary cell proteins or any component of this product
  • known immediate or delayed hypersensitivity reaction or idiosyncrasy to products of similar chemical composition as study drug
  • known contraindications to trastuzumab (Herceptin^®)
  • malabsorption syndrome
  • disease significantly affecting gastrointestinal function
  • psychiatric disorder that would preclude study compliance
  • other serious illness or condition
  • concurrent biologic therapy
  • prior cumulative dose of doxorubicin > 400 mg/m^2 (including liposomal doxorubicin)
  • concurrent hormonal therapy*
  • concurrent glucocorticoids
  • concurrent radiotherapy
  • prior major resection of the stomach or small bowel that could affect absorption of GW572016
  • concurrent cytotoxic therapy
  • other concurrent anticancer therapy
  • other concurrent investigational drugs during and for 28 days after study treatment
  • concurrent administration of any of the following medications or substances:
  • Antibiotics

    • Clarithromycin
    • Erythromycin
    • Troleandomycin
    • Ciprofloxacin
    • Rifampin
    • Norfloxacin
    • Rifabutin
  • HIV antivirals

    • Delaviridine
    • Indinavir
    • Nelfinavir
    • Ritonavir
    • Saquinavir
    • Efavirenz
    • Nevirapine
    • Amprenavir
    • Lopinavir
  • Anticonvulsants

    • Phenytoin
    • Carbamazepine
    • Phenobarbital
  • Antidepressants

    • Fluoxetine
    • Nefazodone
    • Fluvoxamine
  • Antifungals

    • Itraconazole
    • Ketoconazole
    • Fluconazole
    • Voriconazole
  • Antacids (within 1 hour before and after study drug administration)
  • Cimetidine
  • Amiodarone
  • Diltiazem
  • Pioglitazone
  • Hypericum perforatum (St. John's wort)
  • Grapefruit or grapefruit juice
  • Rifabutin
  • Diethyldithiocarbamate
  • Gestodene
  • Mifepristone
  • Modafinil

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00085020

Layout table for location information
United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Layout table for investigator information
Principal Investigator: Mark D. Pegram, MD Jonsson Comprehensive Cancer Center
Publications of Results:
Storniolo AM, Burris HA III, Overmoyer B, et al.: A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-1040, 2005.
Burris III HA, Storniolo AM, Overmoyer EA, et al.: A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. [Abstract] Breast Cancer Res Treat 88 (1): A-3043, 2004.

Layout table for additonal information
Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT00085020    
Other Study ID Numbers: CDR0000367118
First Posted: June 11, 2004    Key Record Dates
Last Update Posted: August 3, 2020
Last Verified: August 2012
Keywords provided by Jonsson Comprehensive Cancer Center:
stage IV breast cancer
male breast cancer
recurrent breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action